ADVERTISEMENT
Sweden
Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.
Xbrane now expects to refile its Lucamzi biosimilar application in March 2026 after FDA manufacturing observations triggered a delay, pushing the potential approval date to September.
Following another complete response letter for its proposed US ranibizumab biosimilar, Xbrane Biopharma plans to finance new projects from its European biosimilar cash flows and rely on top-tier manufacturing partners to reduce regulatory risk.
In this episode of the In Vivo podcast, Sweden-based Cereno Scientific's CEO discusses how his company is turning to an old drug to help patients with rare cardiovascular and pulmonary diseases.
CEO Renée Aguiar-Lucander tells Scrip that the Swedish team is well-equipped to take its desensitisation treatment for the adult kidney transplant to market in the US.
The company’s approach leverages mPGES-1 inhibition to target both inflammation-related pain and lesion load. It is moving into a Phase II trial.
Orexo believes its data further demonstrates the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules.
Xbrane Biopharma is excited about the potential to make more than $100m a year from its proposed biosimilar to Opdivo.
Xbrane Biopharma views Sandoz’s US withdrawal of its Lucentis biosimilar as a key opening for its own ranibizumab candidate, Lucamzi. Management has told investors the move leaves a “void” in the market, as Xbrane await potential FDA approval and launch.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.
In an exclusive interview, Iconovo CEO Johan Wäborg outlines the company’s strategy to become a leader in dry powder inhalation by focusing on platform development, reformulated therapies, and B2B licensing, with a plan to break even by 2027.